ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,26%
Bitcoin
66.947,25
2,62%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Denali Therapeutics Inc (DNLI)

  7. Denali Therapeutics Inc (DNLI) News

DNLI

Denali Therapeutics (DNLI)

Denali Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DNLI
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
07/05/202422h01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/05/202414h00GlobeNewswire Inc.Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialNASDAQ:DNLIDenali Therapeutics Inc
01/03/202422h51Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414h05GlobeNewswire Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414h00GlobeNewswire Inc.Denali Therapeutics Announces $500 million Private Placement Equity FinancingNASDAQ:DNLIDenali Therapeutics Inc
16/02/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
16/02/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
16/02/202403h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
16/02/202403h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202422h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202422h43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202402h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202402h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202402h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
12/02/202422h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
07/02/202414h00GlobeNewswire Inc.Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
01/02/202414h00GlobeNewswire Inc.Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
13/01/202402h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
11/01/202423h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202422h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202401h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202401h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202401h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
10/01/202401h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
08/01/202414h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
08/01/202414h00GlobeNewswire Inc.Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage DiseasesNASDAQ:DNLIDenali Therapeutics Inc
06/01/202402h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DNLI

Kürzlich von Ihnen besucht

PM
XAUUSD
Gold vs US Dollar
TG
DBK
Deutsche Bank
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
BNPQY
BNP Paribas (QX)
TG
BAS
BASF
NYSE
DIS
Walt Disney
DBI
TDXP
Tec DAX
TG
NOV
Novo Nordisk
NASDAQ
TSLA
Tesla
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
DBI
MDAX
MDAX
TG
RHM
Rheinmetall
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten